Treatment of Severe Depression in Adolescents

Initial Treatment Strategy

The American Academy of Pediatrics recommends combination therapy with fluoxetine plus cognitive-behavioral therapy (CBT) for severe depression in adolescents, achieving a 71% response rate compared to 35% for placebo 1, 2
Combination therapy (fluoxetine + CBT) is superior to either treatment alone and should be initiated immediately for severe depression, as it demonstrates significantly greater improvement in depressive symptoms and the most favorable risk-benefit profile 1
Fluoxetine is the only FDA-approved antidepressant for children and adolescents with depression and has the strongest evidence base among all antidepressants tested in this population 2
Monotherapy with fluoxetine alone (60.6% response rate) is superior to CBT alone (43.2% response rate) when combination therapy is not feasible 1

The treatment guidelines recommend starting fluoxetine at 10 mg daily, then increasing to 20 mg daily after 1 week, which is the effective dose for most adolescents 2
Dose increases of 10-20 mg increments can be made at no less than weekly intervals if needed, with a maximum dose of 60 mg daily 2

Regular in-person assessments are necessary to evaluate ongoing depressive symptoms, suicide risk, adverse effects, treatment adherence, and environmental stressors, with the first assessment within 1 week of treatment initiation 2
The FDA black box warning emphasizes increased risk of suicidal thinking and behavior during early antidepressant treatment, though meta-analysis shows 6 times more teenagers benefit from antidepressants than are harmed 1, 3
Common adverse effects to monitor include nausea, headaches, behavioral activation, insomnia, and somnolence 2

Immediate consultation with psychiatry is necessary for severe depression with complicating factors such as coexisting substance abuse, psychosis, or active suicidality requiring inpatient admission 2
Active suicidal ideation with plan or intent requires immediate psychiatric evaluation and may necessitate hospitalization for safety 2

An adequate trial of antidepressant treatment should last at least 8 weeks at optimal dosage before concluding treatment is ineffective 2
If no improvement after 6-8 weeks despite adequate treatment, exploration of poor adherence, comorbid disorders, or ongoing conflicts/abuse is necessary before changing the treatment plan 2
For partial response to maximum tolerated SSRI dosage, adding evidence-based psychotherapy is recommended if not already initiated 2

Medication should be continued for at least 6-12 months after achieving response, as the greatest risk of relapse occurs in the first 8-12 weeks after discontinuation 2, 3
All SSRIs must be slowly tapered when discontinued to prevent withdrawal effects including dizziness, nausea, and mood changes 2, 3

Escitalopram is FDA-approved for adolescents aged 12 years and older and showed superiority to placebo (64% vs 53% response rate) 1, 2
Sertraline may be considered with a starting dose of 25 mg, effective dose of 50 mg, and maximum dose of 200 mg 2
Paroxetine, duloxetine, and venlafaxine should be avoided as first-line agents due to higher rates of intolerable adverse effects 1, 4

Starting at adult doses rather than lower adolescent-specific doses increases the risk of adverse events and deliberate self-harm 2, 3
Failing to address comorbid conditions, poor adherence, or ongoing environmental stressors will undermine treatment response regardless of medication choice 2
Inadequate follow-up monitoring, particularly in the first 4-8 weeks, misses critical opportunities to detect emerging suicidality or adverse effects 2
Premature discontinuation before completing an adequate 8-week trial at therapeutic doses leads to false conclusions about treatment failure 2

Incorporating lifestyle modifications, including structured physical exercise, sleep hygiene optimization, and adequate nutrition, is recommended as foundational elements 3
Collaborative care models that include parent involvement, regular follow-up with care managers, and choice of treatment type show superior outcomes at 6 and 12 months 2